Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Occupational Exposure Concerns

The legacy of general health and science information dissemination has long served as a foundational pillar for public awareness, offering broad insights into wellness, disease prevention, and therapeutic interventions. Within this expansive domain, discussions surrounding pharmaceutical safety and adverse effects have traditionally been framed in terms of population-level risk and clinical management. However, as the landscape of health communication evolves, there is a growing need to bridge these general principles with more specialized, context-specific concerns—particularly those arising from occupational and environmental exposures. This transition requires a shift from abstract, population-based narratives to focused inquiries into how specific substances interact with biological systems under distinct exposure scenarios. In the realm of mass production, where chemical compounds are synthesized and handled at scale, the potential for unintended health consequences becomes a critical consideration. The pivot from general health education to occupational exposure concern is thus not merely a narrowing of scope but a necessary adaptation to address the unique risks faced by workers and communities in industrial settings. By leveraging the foundational knowledge of general health science, we can now examine how prolonged or high-level contact with certain agents may precipitate adverse outcomes, without delving into mechanistic specifics. This approach ensures that the transition remains grounded in established principles while opening avenues for targeted investigation into exposure-related health effects.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general framework of pharmaceutical safety, we now turn to a specific medication—Fosamax (alendronate)—and its association with a serious adverse effect: osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation often involves pain, swelling, and infection in the jaw, with exposed bone that fails to heal over weeks to months. Diagnosis is typically based on clinical examination and imaging, with a history of bisphosphonate exposure being a key consideration.

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate suppress bone turnover, which can impair the jawbone's ability to remodel and repair microdamage. This is particularly relevant in the jawbone, which undergoes constant mechanical stress from chewing and is subject to dental procedures and infections. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate have examined effects on jawbone properties such as tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the jawbone's structural and material properties, potentially increasing susceptibility to ONJ.

Risk Factors and Clinical Considerations

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. However, the warning does not provide specific incidence rates or detailed guidance on monitoring for ONJ in all patients. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known risk, its occurrence in clinical trials was not statistically elevated compared to placebo, possibly due to the rarity of the event or the specific populations studied.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as the condition improves upon discontinuation and recurs upon re-exposure. However, ONJ can also occur spontaneously in individuals not taking bisphosphonates, complicating the attribution of causation in individual cases. Other risk factors, such as dental procedures or infections, often coexist, making it difficult to isolate Fosamax as the sole cause. In summary, the evidence indicates that Fosamax exposure is linked to osteonecrosis of the jaw through mechanisms involving suppressed bone turnover and altered jawbone properties. The prescribing information includes warnings about this risk, but the adequacy of these warnings may be questioned given the variability in onset and the presence of other risk factors. For affected patients, the timeline of exposure to harm and the response to drug discontinuation provide important considerations for establishing causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction or local infection. Fosamax and other bisphosphonates are linked to ONJ through mechanisms involving suppressed bone turnover and altered jawbone properties, which impair the jawbone's ability to remodel and repair microdamage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation between Fosamax and ONJ established in affected patients?

Causation is supported by a temporal relationship: symptoms can appear from one day to several months after starting Fosamax, improve upon discontinuation, and recur upon re-exposure. However, ONJ can also occur spontaneously, and other risk factors often coexist, making individual attribution challenging (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.